Form 4: IQVIA Controller Granted Stock Appreciation Rights

IQVIA Holdings Inc.'s SVP, Corporate Controller, Keriann Cherofsky, was granted 2,795 Stock Appreciation Rights with an exercise price of $192.67.

Summary

• Keriann Cherofsky, SVP, Corporate Controller of IQVIA Holdings Inc. (IQV), was granted 2,795 Stock Appreciation Rights (SARs).
• The transaction date for this grant was February 9, 2026.
• Each Stock Appreciation Right has an exercise price of $192.67.
• The SARs will vest in three annual installments, with the first installment beginning on February 9, 2027.
• The expiration date for these Stock Appreciation Rights is February 9, 2036.
• Following this transaction, Keriann Cherofsky beneficially owns 2,795 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard executive compensation event, aligning management's interests with long-term shareholder value, which is generally a positive governance practice and does not indicate any immediate operational or financial concerns.

Positives

• The grant of Stock Appreciation Rights aligns the interests of the SVP, Corporate Controller, with those of shareholders, as the value of the SARs is tied to the future appreciation of IQVIA's common stock.
• Equity compensation is a standard practice for retaining key executives and incentivizing long-term performance.

Negatives

• The Stock Appreciation Rights do not represent immediate ownership of common stock and their value is contingent on the company's stock price increasing above the exercise price of $192.67.
• There is no immediate cash value associated with this grant for the recipient.

Risks

• The value of the Stock Appreciation Rights is subject to market volatility and the future performance of IQVIA Holdings Inc.'s common stock.
• If the company's stock price does not appreciate significantly above the exercise price, the SARs may have limited or no intrinsic value upon vesting or exercise.

Future Outlook

The grant of Stock Appreciation Rights is intended to incentivize the SVP, Corporate Controller, to contribute to the long-term growth and stock price appreciation of IQVIA Holdings Inc., aligning future performance with executive compensation.

Industry Context

StockSavvy.ai notes that equity grants like Stock Appreciation Rights are common executive compensation tools in the pharmaceutical and healthcare technology sectors, aligning executive incentives with shareholder value creation and promoting long-term retention.

Comparison to Industry Standards

• StockSavvy.ai observes that granting Stock Appreciation Rights with a multi-year vesting schedule is a standard practice for executive compensation across large-cap pharmaceutical and healthcare IT companies, similar to practices at companies like Thermo Fisher Scientific or Veeva Systems, aiming to retain talent and incentivize long-term performance.
• The exercise price set at the grant date's market price is typical for SARs, ensuring that the executive benefits only from future stock price appreciation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced executive alignment with long-term stock performance.
• Employees (Executive): Direct benefit through equity compensation, incentivizing retention and performance.

Next Steps

• The Stock Appreciation Rights will begin to vest in annual installments starting February 9, 2027.
• The recipient may choose to exercise the vested SARs at any point before their expiration on February 9, 2036, provided the stock price is above the exercise price.

Key Dates

Recommendation

This Form 4 reports a routine grant of equity compensation to a corporate officer, which is a standard practice for aligning management incentives. It does not provide new information that would fundamentally alter the investment thesis for IQVIA Holdings Inc., thus a 'hold' recommendation is appropriate.

Keywords

IQVIA, IQV, Stock Appreciation Rights, SARs, Insider Transaction, Form 4, Equity Grant, Executive Compensation